Related Experiment Videos
Recent advances in AIDS vaccine research and development
M I Johnston1, J S Noe, J Y Killen
1Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
AIDS Research and Human Retroviruses
|January 1, 1994
Summary
Developing an AIDS vaccine is critical. Research shows progress with 12 candidate vaccines in trials, focusing on safety, immune response, and future efficacy considerations.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- An urgent need exists for an Acquired Immunodeficiency Syndrome (AIDS) prophylactic vaccine to combat the growing epidemic.
- The 1993 Conference on Advances in AIDS Vaccine Development highlighted progress and remaining challenges in vaccine research.
Purpose of the Study:
- To review recent advances in AIDS vaccine research and development.
- To outline factors influencing the National Institute of Allergy and Infectious Diseases' (NIAID) decisions on advancing candidates into Phase III trials.
Main Methods:
- Review of current state-of-the-art vaccine research.
- Analysis of ongoing Phase I/II clinical trials for candidate AIDS vaccines.
- Consideration of new vaccine strategies, including mucosal immunity and novel formulations.
Main Results:
- Approximately 12 candidate AIDS vaccines are in Phase I/II clinical trials, demonstrating safety and immunogenicity.
- Progress includes establishing domestic and international sites for future efficacy trials.
- Preparatory activities for efficacy trials are underway.
Conclusions:
- The development of an effective AIDS vaccine is progressing, with candidates entering advanced trials.
- Ease of administration, cost, and ethical considerations are crucial for Phase III trial planning.
- NIAID's strategic position on advancing candidates into Phase III trials will be shaped by these complex factors.